Introduction
============

Puncture site-related vascular complications occur in 3.1--9.7% of patients who underwent neuroendovascular therapy.^[@B1]^ Our previous data analysis from the Japanese Registry of Neuroendovascular Therapy (JR-NET)1 & 2 showed that access site complications occurred in 0.63% of all procedures.^[@B2]^ Retroperitoneal hematoma may result in death due to the massive bleeding. In recent years, hemostatic devices have been developed and improved, and showed efficacy in numerous meta-analyses, but retroperitoneal hematoma still requires much caution.^[@B1],[@B3]--[@B5]^ In Japan, a prospective study on the access-site hemostatic device Angio-Seal (Terumo, Tokyo, Japan) proved its efficacy in neurondovascular therapy.^[@B6]^ JR-NET3 includes retrospectively registered studies on neuroendovascular therapy conducted by the Japanese Society for Neuroendovascular Therapy from January 2010 to December 2013. The registration parameters included disease-specific and cross-sectional parameters common in all diseases. In this article, puncture site-related vascular complications in JR-NET3 (a cross-sectional parameter) are analyzed.

Materials and Methods
=====================

Data of 36,708 patients out of all 43,303 cases registered in JR-NET3 were included in the evaluation. Puncture site-related complications included hemorrhagic complications, ischemic complications, and infections. If the hemostatic method was not described, it was not assessed. The presence or absence of an access site complication, age, sex, treatment facility (main hospital or satellite hospital), timing of surgery (scheduled or emergency), investigator (supervisor/specialist, or non-specialist), treatment (cerebral aneurysm embolization, arteriovenous malformation embolization, spinal lesion, dural arteriovenous fistula, intracranial tumor, carotid artery stenting (CAS), extracranial percutaneous transluminal angioplasty (PTA), intracranial PTA, acute recanalization therapy, spasm treatment, or other), outcome of complications (asymptomatic, transiently symptomatic, moderate disability, severe disability, or death), and the effect of complications on the treatment outcome were assessed. For puncture-related complications, we also examined how they were treated (conservative treatment, additional endovascular therapy, open surgery). Out of all patients who received treatment (cerebral aneurysm embolization, carotid artery stenting, extracranial PTA, and intracranial PTA), 25,348 cases with available data regarding antiplatelet therapy were included in the assessment of preoperative use of antiplatelet drugs. These variables were analyzed using Chi-square test for categorical variables and *t*-test for continuous variables, with a significance level of *P* \<0.05 (SPSS Ver. 22, IBM, Armonk, NY, USA) used in statistical analysis.

Results
=======

Puncture site-related complications occurred in 315 (0.73%) of all 43,303 cases ([Table 1](#T1){ref-type="table"}). Incidence of puncture site-related complications was not affected by the facility where operation was done, timing of operation, and the operator. Regarding the treatment, CAS (95 patients, 1.1%, *P* \<0.01) and extracranial PTA (21 patients, 1.4%, *P* \<0.01) were associated with a significantly higher incidence of complications, while parent artery aneurysm occlusion (one patient, 0.06%, *P* \<0.05), arteriovenous malformation (one patient, 0.1%, *P* \<0.01), and acute recanalization therapy (22 patient, 0.6%, *P* \<0.01) were associated with a significantly lower incidence. The treatment for puncture site-related complications was conservative in 125 patients (40.0%), endovascular in 42 patients (13.3%), and open surgery in 16 patients (5.1%). The treatment outcome was asymptomatic or transiently symptomatic in 90.5% of patients, permanent disability in 22 patients (0.05%), and fatal in six patients (0.01%). The incidence of puncture site-related complications according to the use of antiplatelet drugs is shown in [Figure 1](#F1){ref-type="fig"}. It was significantly different between the patients without therapy for complications (17 patients, 0.32%), those who received 1 or 2 drugs (202 patients, 1.16%), and those who received 3 or more drugs (28 patients, 1.47%). At the time of acute revascularization, combination of treatment with tissue plasminogen activator (tPA) had no effect on puncture site-related complications (0.6% with tPA vs 0.6% without tPA, *P*-value = 0.96; [Table 2](#T2){ref-type="table"}). In the carotid stent group, there was no difference in the incidence of puncture complications in the use of sheath equal or larger than 8 Fr. (19 cases, 1.2%) and the sheath smaller than 8 Fr. (75 cases, 1.1%). Regarding the age, there was no difference in the frequency of complications between those aged 75 or older (68 cases, 0.7%) and those younger than 75 (190 cases, 0.7%). Although 40% of the puncture complications were treated conservatively, 13% were treated endovascularly and 5% underwent direct surgery.

Discussion
==========

In this study, the incidence of puncture site-related complications was 0.73%, which is substantially lower than previously reported 3.1--9.7%.^[@B1],[@B2],[@B4],[@B7],[@B8]^ Compared with our previous study based on JR-NET1 & 2 data, puncture site-related complications had also very low incidence of 0.63%.^[@B6]^ As a result of strict management of puncture complications in Japanese endovascular treatment facilities, low incidence of puncture site-related complications is estimated. CAS and extracranial PTA are associated with higher incidence of complications mainly due to intraoperative heparinization, the use of multiple antiplatelet agents, larger diameter sheaths, and peripheral atherosclerosis. There was no difference in puncture complications related with alteplase administration in acute revascularization therapy.

In case of acute revascularization, a 9-Fr guiding catheter with a balloon is often used in Japan. Since a puncture site hemostatic device is applicable only for catheters up to 8 Fr, it was estimated that using catheters over 8 Fr would lead to puncture site complications, but it turned to be similar to other groups.

There is concern about an increase in complications at the puncture site due to the intravenous administration of alteplase prior to endovascular treatment. In this study, the use of tPA did not lead to the increase in puncture site complications. The results were in line with those in the recent publication.^[@B9]^

Recent reports have shown that hemostasis can be achieved using various hemostatic devices without increasing complication rate.^[@B9],[@B10]^

In the carotid stent group, there was no difference in the incidence of puncture site complications between 8 and 6 Fr sheath use, presuming that the hemostatic device was effectively used. In our previous study on the effectiveness of Angio-Seal, it was shown that the occurrence frequency of the puncture site complications is not related to the sheath size.^[@B6]^

It was estimated that the progression of arteriosclerosis increasing with age may cause an increase in puncture-related complications, but this study did not show any increase in complications depending on age.

The treatment outcome was asymptomatic or transiently symptomatic in 90.5%, but caused disability in 7.0%. Death-related access site complications occurred in six patients (0.016%), but those patients had not only access site, but also other (ischemic and/or hemorrhagic) complications. In this study, it cannot be definitively concluded whether the treatment outcome was affected by puncture site-related complications or not, because some patients had not only puncture site-related, but also other complications. Most puncture site complications resolved after conservative therapy, but in a few cases additional endovascular treatment or open surgery were necessary.

Looking at the annual trends of retrospectively registered studies in JR-NET1--3, conducted from 2005 to 2012, the same trend was found in occurrence frequency, severity, and cause with the respect to puncture complications.^[@B2]^ Although there are no innovations and advances in development of hemostasis devices, vascular puncture-related complications have been strictly managed in Japanese endovascular treatment facilities, and thus a low puncture complication rate has been maintained.

Regarding the limitations, it was a retrospective study based on the registry data, and no description whether the hemostasis was done by the main operator or the assistant was provided. The evaluation criteria for puncture site complications in particular are ambiguous and may be underestimated due to oversight. There was no distinction between using a hemostatic device or manual compression to achieve hemostasis. Regarding puncture site complications, some data may be missing, which may affect statistical analysis.

Conclusion
==========

The incidence of puncture site vascular complications was 0.73%. These complications resulted in permanent disability in 22 patients (0.06%) and death in six patients (0.017%). CAS, extracranial PTA, and use of antiplatelet drugs were associated with higher incidence of complications. Compared with JR-NET1--3 data were comparable in terms of puncture site complications.
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###### 

Characteristics of puncture site-related complications

                                       Total            Complications (%)   Puncture site complication (%)   \% In access site complication   Data unavailable   *P*-value
  ------------------------------------ ---------------- ------------------- -------------------------------- -------------------------------- ------------------ -----------
  Patients                             36708                                                                                                                     
  Cases                                43303            3922 (10.7%)        315 (0.7)                                                         0                  
  Age ± SD                             65.2 ± 14.2                                                                                            748                
  Male                                 18,626 (50.7%)                                                                                         710                
  Facility                                                                                                                                                       
    Main                               34403            3350 (9.7)          269 (0.8)                        85.4                             52                 0.57
    Satellite                          2253             572 (25.4)          20 (0.9)                         6.3                                                 
  Timing                                                                                                                                                         
    Schedule                           24551            2396 (9.8)          193 (0.8)                        61.3                             40                 0.84
    Emergency                          12117            526 (4.3)           96 (0.8)                         30.5                                                
  Operator                                                                                                                                                       
    Supervisor/Specialist              34026            2023 (5.9)          301 (0.9)                        95.6                             718                0.43
    Non-specialist                     1964             171 (8.7)           14 (0.7)                         4.4                                                 
  Treatment                                                                                                                                   0                  
    Aneurysm embolization              17348            1803 (10.4)         140 (0.8)                        7.8                                                 NS
    Aneurysm parent artery occlusion   1315             260 (19.8)          8 (0.5)                          3.1                                                 \<0.01
    Arteriovenous malformation         1456             128 (8.8)           1 (0.1)                          0.8                                                 \<0.01
    Spinal lesion                      275              22 (8.0)            0                                0.0                                                 NS
    Dural AVF                          2776             129 (4.6)           4 (0.1)                          3.1                                                 NS
    Tumour                             1657             61 (3.7)            4 (0.1)                          6.6                                                 NS
    Carotid artery stent               8889             674 (7.6)           95 (1.1)                         14.1                                                \<0.01
    Extracranial PTA                   1491             97 (6.5)            21 (1.4)                         21.6                                                \<0.01
    Intracranial PTA                   1268             134 (10.6)          6 (0.5)                          4.5                                                 NS
    Acute recanalization therapy       3974             508 (12.8)          22 (0.6)                         4.3                                                 \<0.01
    Apasm                              1804             42 (2.3)            0                                0.0                                                 NS
    Other                              1050             64 (6.1)            10 (1.0)                         15.6                                                (−)
  Outcome                                                                                                                                     2                  
    Asymptomatic                                                            78                               24.8                                                
    Transient symptom                                                       207                              65.7                                                
    Moderate disability                                                     12                               3.8                                                 
    Severe disability                                                       10                               3.2                                                 
    Dead                                                                    6                                1.9                                                 

###### 

Sub-analysis of puncture site-related complications frequency

                                                Cases      Puncture site complications (%)   Data unavailable   *P*-value
  ---------------------------------- ---------- ---------- --------------------------------- ------------------ -----------
  Acute recanalization therapy       tPA (+)    1396       8 (0.6)                           0                  0.96
  tPA (−)                            2492       14 (0.6)                                                        
  Carotid artery stent sheath size   \<8 Fr     1597       19 (1.2)                          667                0.85
  ≥8 Fr                              6625       75 (1.1)                                                        
  Age                                \<75 y/o   26027      190 (0.7)                         57                 0.64
  ≥75 y/o                            9947       68 (0.7)                                                        
